Feed Insights Top Reports Pricing

⌘K

08:40:02·387d

ANALYSTRatingvia Quantisnow

Dexcom downgraded by Oppenheimer

ByQuantisnow·Wall Street's wire, on your screen.

DXCM· DexCom Inc.

Health Care

#watchlistBeagle is online

BeagleApp8:40 AM

Heads up - $DXCM just picked up a new analyst rating. Here is the headline that moved it:

Dexcom downgraded by Oppenheimer

Sourced from the filing - want the 30-second brief? Never financial advice.

Hire Beagle to watch $DXCM

👀7🚀4🐶3

Plus alert sent

Quantisnow Plus members were alerted at 08:40:03 ET - 1.0s after publication.

Sign up for Plus

beagle.

by Alamere Labs

Now hiring

Your first full-time market-watch teammate

Market research that briefs you, before the bell.

Beagle watches $DXCM across price, news, SEC filings and the macro calendar, drafts the morning brief, and pings you the moment a name moves - sourced every time, and never financial advice.

Price levelsSEC filingsBreaking newsMacro calendar

Hire Beagle See an alertLives in Slack & Teams

Free Quantisnow account

Get notified the moment DXCM files

Real-time alerts on SEC filings, FDA approvals, analyst ratings, insider trades, and press releases. Follow any ticker. No credit card.

Sign up free Log in

Original source

This insight was delivered by Quantisnow - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DXCM (DexCom Inc.) and more on Quantisnow.

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Related

EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds Follow on Google News

Top lists

Trending By market cap Active companies Insider purchases FDA approvals Short volume screener Sectors Market reports

Browse

By event category By exchange Earnings calendar Dividend tracker Insider tracker IPO calendar Compare stocks

Publish

Publish an article Amend a newsitem Pricing Guidelines Terms

Company

About Pricing Refer a trader25%Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022